Aktienanalyse zu Virax Biolabs Group Ltd (VRAX)VRAXVirax Biolabs Group Ltd

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1). It operates in the Healthcare sector (IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES industry).

VRAX is not a good buy right now due to its extremely low RSI of 19.69, indicating oversold conditions, and a staggering year-to-date change of -91.67%. The stock has also experienced a 5-day decline of 33.88%, suggesting a strong downward momentum. The main risk is its gross margin of -3381.20%, indicating severe profitability issues that could deter long-term investors.